Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis.
Nucl Med Commun
; 45(8): 651-657, 2024 Aug 01.
Article
in En
| MEDLINE
| ID: mdl-38757155
ABSTRACT
Portal vein thrombosis, a relatively frequent complication associated with hepatocellular carcinoma (HCC) and liver cirrhosis, is recognized as a significant global health concern. This is mainly due to these conditions' high prevalence and potentially severe outcomes. The aim of our study was to conduct a comprehensive literature review to evaluate the efficacy, accuracy, and clinical implications of 18F-FDG PET-CT in diagnosing and managing portal vein tumor thrombosis (PVTT) in patients with HCC. HCC, which accounts for 80% of liver malignancies, ranks as the fourth most prevalent cancer globally and is a significant contributor to cancer-related mortality. The majority of HCC patients are diagnosed at an advanced stage, leading to a deterioration in patient outcomes. Involvement of the portal vein is also a significant negative factor. This review analyzes the application of 18F-FDG PET-CT in the detection and management of PVTT in patients with HCC, with an emphasis on the importance of the maximum standardized uptake value as an essential diagnostic and prognostic marker. 18F-FDG PET-CT is invaluable for detecting recurrence and guiding management strategies, particularly in patients with high-grade HCC, and plays a pivotal role in differentiating malignant portal vein thrombi from their benign counterparts.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Portal Vein
/
Carcinoma, Hepatocellular
/
Fluorodeoxyglucose F18
/
Venous Thrombosis
/
Positron Emission Tomography Computed Tomography
/
Liver Neoplasms
Limits:
Humans
Language:
En
Journal:
Nucl Med Commun
Year:
2024
Document type:
Article
Country of publication:
Reino Unido